NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
Biopeople Newsletter January 2020 - Biopeople
Rare Neuromuscular Disease Company NMD Pharma Raises USD 3 Million in Seed Financing Round - Lundbeckfonden
NMD Pharma - Inkef capital
NMD Pharma treats first patient with the firm's most promising drug candidate
NMD Pharma A/S | LinkedIn
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
Prominent Canadian researcher in Denmark: Why I left a top job in California
Thomas Holm Pedersen – CEO – NMD Pharma | LinkedIn
Management — NMD Pharma
Annual Report 2018 by Lundbeckfonden - issuu
NMD Pharma - PIR International
NMD Pharma
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
News — NMD Pharma
Dutch MG Clinical Trial Will Test NMD670 Oral Therapy Candidate
ALS Therapy Developer NMD Pharma Obtains $47 Million in New Financing
Management — NMD Pharma
Foundations invest DKK 280 million in biomedical company
